Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Furberg, Full Drug Safety Committee To Be Present At COX-2 Meeting

Executive Summary

Wake Forest University epidemiologist Curt Furberg will participate with FDA's full Drug Safety & Risk Management Advisory Committee in the upcoming review of the COX-2 inhibitor therapeutic class

You may also be interested in...

FDA Discloses Safety Reviews Of COX-2s Arcoxia, Prexige and Parecoxib

Merck's Arcoxia is linked to an increase in cardiovascular adverse events across multiple analyses, FDA reviewers state in briefing documents for the upcoming COX-2 inhibitor safety review

SMART-er Isotretinoin Risk Management Program To Be Operated By Covance

Covance will develop and operate a single, enhanced risk management program for all four isotretinoin products

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts